Selective anticancer strategies via intervention of the death pathways relevant to cell transformation

被引:35
作者
Li, Q-X [1 ]
Yu, D. H. [1 ]
Liu, G. [1 ]
Ke, N. [1 ]
McKelvy, J. [1 ]
Wong-Staal, F. [1 ]
机构
[1] iTherX Pharmaceut Inc, Drug Dev, San Diego, CA 92121 USA
关键词
cancer; target; drug; cell adhesion; UPR; GRP78; virotherapy;
D O I
10.1038/cdd.2008.48
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Apoptosis is an important physiological process that promotes tissue homeostasis by eliminating unnecessary or malfunctioning cells. Abnormality in this process contributes to tumorigenesis, as well as the resistance to cancer treatment by radiation and chemotherapy. Restoration of normal apoptosis would not only promote cancer cell death and halt tumor progression, but also increase the response to many current cancer therapies. Although apoptosis induction is an important principle of currently used radiation and chemotherapy treatment, uncovering the mechanisms that govern this process, and which are lost during transformation, represents an important direction for realizing improved therapies for the future. This article first briefly reviews aspects of current discovery strategies for new anticancer therapeutics based on intervening in cell death pathways, and then discusses in more detail several cancer-relevant death pathways, which are disabled during transformation and which can be targeted therapeutically. These include anoikis/cell adhesion; energy metabolism and the unfolded protein response. Finally, we introduce a new concept, which utilizes cancer-specific apoptosis induced by oncolytic viruses. The discussion of these topics involves novel targets, compounds and virotherapy.
引用
收藏
页码:1197 / 1210
页数:14
相关论文
共 108 条
[91]   Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis [J].
Shuda, M ;
Kondoh, N ;
Imazeki, N ;
Tanaka, K ;
Okada, T ;
Mori, K ;
Hada, A ;
Arai, M ;
Wakatsuki, T ;
Matsubara, O ;
Yamamoto, N ;
Yamamoto, M .
JOURNAL OF HEPATOLOGY, 2003, 38 (05) :605-614
[92]   Second-generation shRNA libraries covering the mouse and human genomes [J].
Silva, JM ;
Li, MZ ;
Chang, K ;
Ge, W ;
Golding, MC ;
Rickles, RJ ;
Siolas, D ;
Hu, G ;
Paddison, PJ ;
Schlabach, MR ;
Sheth, N ;
Bradshaw, J ;
Burchard, J ;
Kulkarni, A ;
Cavet, G ;
Sachidanandam, R ;
McCombie, WR ;
Cleary, MA ;
Elledge, SJ ;
Hannon, GJ .
NATURE GENETICS, 2005, 37 (11) :1281-1288
[93]  
Song MS, 2001, CANCER RES, V61, P8322
[94]   Infection with oncolytic herpes simplex virus-1 induces apoptosis in neighboring human cancer cells: A potential target to increase anticancer activity [J].
Stanziale, SF ;
Petrowsky, H ;
Adusumilli, PS ;
Ben-Porat, L ;
Gonen, M ;
Fong, Y .
CLINICAL CANCER RESEARCH, 2004, 10 (09) :3225-3232
[95]   UNUSUAL RETENTION OF RHODAMINE-123 BY MITOCHONDRIA IN MUSCLE AND CARCINOMA-CELLS [J].
SUMMERHAYES, IC ;
LAMPIDIS, TJ ;
BERNAL, SD ;
NADAKAVUKAREN, JJ ;
NADAKAVUKAREN, KK ;
SHEPHERD, EL ;
CHEN, LB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1982, 79 (17) :5292-5296
[96]   Nur77 as a survival factor in tumor necrosis factor signaling [J].
Suzuki, S ;
Suzuki, N ;
Mirtsos, C ;
Horacek, T ;
Lye, E ;
Noh, SK ;
Ho, A ;
Bouchard, D ;
Mak, TW ;
Yeh, WC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (14) :8276-8280
[97]   Mechanism for generation of hydrogen peroxide and change of mitochondrial membrane potential during rotenone-induced apoptosis [J].
Tada-Oikawa, S ;
Hiraku, Y ;
Kawanishi, M ;
Kawanishi, S .
LIFE SCIENCES, 2003, 73 (25) :3277-3288
[98]   Decitabine activates specific caspases downstream of p73 in myeloid leukemia [J].
Tamm, I ;
Wagner, M ;
Schmelz, K .
ANNALS OF HEMATOLOGY, 2005, 84 (Suppl 1) :47-53
[99]   HYPOXIA AND DRUG-RESISTANCE [J].
TEICHER, BA .
CANCER AND METASTASIS REVIEWS, 1994, 13 (02) :139-168
[100]   Oncolytic herpes simplex virus vectors for cancer virotherapy [J].
Varghese, S ;
Rabkin, SD .
CANCER GENE THERAPY, 2002, 9 (12) :967-978